Medication adherence and non-Vitamin K antagonist oral anticoagulants: What do we really know?

Europace

Volumn 17, Issue 8, 2015, Pages 1316-1317

  Baker, William L ^a   Coleman, Craig I ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CLOPIDOGREL; CYTOCHROME P450 2C19; TICAGRELOR; ANTICOAGULANT AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; HUMAN; LETTER; MEDICATION COMPLIANCE; PRIORITY JOURNAL; DRUG ADMINISTRATION; THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; THROMBOEMBOLISM;

EID: 84939614452     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv108     Document Type: Letter

References (5)

1. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twicedaily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
2. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
3. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-83
4. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51
5. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28:669-80.